ع
Silicone rupture usually produces no symptoms, and the newest implants are engineered to blend into breast tissue, which leaves imaging as the main route to detection.
Breast augmentation was the third most common surgical procedure worldwide in 2024, with 1.66 million operations recorded in the ISAPS Global Survey, and 54 percent of them performed on women aged 18 to 34. That age profile commits the average patient to a device requiring surveillance for decades. The evidence on whether the surveillance happens is poor.
A patient survey published in Plastic and Reconstructive Surgery found that of 109 women who had received silicone implants, 15.6 percent had undergone an MRI at any point after surgery, and 5.9 percent had done so within the timeframe recommended by the US Food and Drug Administration. A separate survey of American plastic surgeons found fewer than 40 percent recommend the screening interval their own regulator sets out.
The schedule most patients do not keep
The FDA position is that patients with silicone implants should have a first ultrasound or MRI five to six years after surgery and repeat imaging every two to three years thereafter, whether or not they have symptoms. The agency states that MRI is the most effective method for detecting silent rupture, with ultrasound an acceptable alternative for asymptomatic patients.
Dr. Dora Evangelidou, a consultant plastic and reconstructive surgeon practising at CosmeSurge Hospital Jumeirah in Dubai, applies a tighter routine. “If you have an implant, you need to follow your breast tests and breast examination every year or every six months with ultrasound and mammogram if you are above 39 years,” she says, adding cross-sectional imaging on top of that: “for the people that have an implant, also an MRI, it’s a good recommendation after the fifth year.”
Her reasoning is a detection argument rather than a scheduling one. “MRI can see ruptures much easier than mammogram or ultrasound,” she says. A prospective study at the Universidade de São Paulo, which imaged 44 asymptomatic patients and then correlated findings with surgery, reported sensitivity of 20 percent for mammography, 30 percent for ultrasound and 64 percent for MRI.
How often implants actually fail
The device data support routine follow-up. Final ten-year results from Allergan’s Natrelle Core Study, in which roughly a third of subjects underwent scheduled MRI, recorded a rupture rate of 13.0 percent by subject and 7.7 percent by implant, with 81.8 percent of augmentation patients still carrying an original implant at ten years. A 2022 study that scanned 584 women with high-resolution ultrasound put the silent rupture rate at 10.6 percent. Beyond the ten-year mark, the FDA notes, rupture data are not available at all.
What a rupture finding actually triggers
Detection does not automatically mean an operating theatre, a distinction Evangelidou draws sharply. “If we have a rupture, it can be either intracapsular, inside the capsule of the breast, or extracapsular,” she says. “If it’s intracapsular, then we can choose the path of observation instead of emergency surgery. If it’s extracapsular, then we can think of replacing it and removing the ruptured implant sooner than later.”
Softer devices shift the burden onto imaging
The imaging question has grown more consequential as implant design has changed. “Old generation of implants, they have a fixed shape, a very fixed shape,” Evangelidou says. “You cannot change it, no matter how much you pull or push. So you can feel it, because it’s a distinct entity in your breast.” Current SmoothSilk Ergonomix2 devices, used in the Preservé and MIA Femtech procedures she performs, sit in what the manufacturer markets as its SuperSilicones range and are formulated for elongation and tissue adaptation. “That means they don’t really maintain a very resistant shape,” she says. “It’s under the super silicone category that blends with your breast tissue.”
She frames the choice as a patient preference: “Do you want to feel the implant and palpate the implant and see the implant sometimes? Or do you really want a nice one unit breast with implant all together?” The clinical consequence follows either way. The less a device announces itself under the hand, the less a physical examination contributes and the more the imaging calendar carries.
Where the case for MRI is weaker
The MRI-first premise is contested. A 2024 study that scanned 104 women with both modalities on the same day found ultrasound reached 96 percent accuracy against MRI, with 95 percent sensitivity and 96 percent specificity. Reviews in Annals of Surgical Oncology put MRI at US$2,000 to US$6,000, usually paid out of pocket after cosmetic augmentation. On that reading the binding constraint is not access to MRI but access to any imaging at all.
The regional dimension sharpens it. Dubai received 691,478 health tourists in 2023 who spent AED 1.03 billion, according to Dubai Health Authority figures, and long-term device surveillance assumes a patient remains within reach of the record of her own operation. The registries generating durable implant data are concentrated in Australia, the Netherlands, Sweden, the United Kingdom and the United States.
Appetite is not the obstacle. In the same 584-woman study, 99.5 percent said they wanted to know if an implant had ruptured and 95.2 percent wanted a ruptured device removed. Against a 5.9 percent adherence rate, the gap is one of process, not of will.
